SLDB Solid Biosciences Inc.
Price Chart
Executive Summary
Solid Biosciences reported financial results for Q4 and full year 2025, highlighted by strong pipeline progress across its gene therapy programs, including positive interim Phase 1/2 data for SGT-003 in Duchenne, first patient dosed in the FALCON trial for SGT-212 in Friedreich’s ataxia, and upcoming trials for SGT-501 in CPVT. The company also completed a $240 million private placement, extending its cash runway into H1 2028.
Key Financial Metrics
Actionable Insight
Investors should monitor upcoming FDA guidance on accelerated approval for SGT-003 and initial clinical readouts from FALCON and ARTEMIS trials in H2 2026. The capital raise eliminates near-term dilution risk and supports value-inflection milestones.
Key Facts
- Positive interim Phase 1/2 INSPIRE DUCHENNE data showed robust microdystrophin expression, restoration of DAPC components, and stabilization of cardiac function.
- First participant dosed in Phase 1b FALCON trial for SGT-212 in Friedreich’s ataxia; well tolerated with no treatment-related adverse events.
- Clinical sites activated for Phase 1b ARTEMIS trial of SGT-501 in CPVT; first dosing expected in Q2 2026.
- Company aligned with FDA on Phase 3 IMPACT DUCHENNE trial design; first dosing expected in April 2026.
- Completed $240 million private placement; combined with $187.9M cash at year-end, extends runway into H1 2028.
- R&D expenses increased to $140.3M in 2025 from $96.4M in 2024, reflecting advancing clinical programs.
- Net loss widened to $174.3M in 2025 from $124.7M in 2024, primarily due to increased R&D spending.
Financial Impact
Cash position strengthened by $240M private placement; total available funds now support operations into mid-2028. R&D spend increased 45% YoY to $140.3M, signaling aggressive pipeline advancement.
Risk Factors
- Clinical trial delays or safety issues could derail development timelines.
- Interim data may not translate into durable or statistically significant results in later stages.
- High cash burn rate requires continued successful execution to maintain runway through pivotal readouts.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259444 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 12, 2026
4w ago
|
Press Release
| $7.38 $6.08 | ▲ +17.62% | ▲ +16.46% | $7.14 (+3.25%) |
|
May 7, 2026
5w ago
|
Press Release
| $7.07 $7.38 | ▲ +4.38% | ▲ +2.88% | $7.14 (+0.99%) |
|
Apr 23, 2026
7w ago
|
DEFA14A
| $7.92 $7.26 | ▼ −8.33% | ▼ −9.24% | $7.14 (−9.85%) |
|
Apr 10, 2026
9w ago
|
8-K
| $8.39 $8.49 | ▲ +1.19% | ▼ −2.10% | $7.14 (−14.90%) |
|
Apr 1, 2026
10w ago
|
EFFECT
| $7.38 $8.10 | ▼ −9.76% | ▼ −5.99% | $7.14 (+3.25%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $7.03 $7.11 | ▲ +1.14% | ▲ +3.29% | $7.14 (+1.56%) |
|
Mar 12, 2026
13w ago
|
8-K
| $7.71 $7.12 | ▼ −7.65% | ▼ −6.67% | $7.14 (−7.39%) |
|
Mar 11, 2026
13w ago
|
Press Release
| $7.72 $7.12 | ▼ −7.71% | ▼ −5.52% | $7.14 (−7.45%) |
|
Mar 6, 2026
14w ago
|
Press Release
| $6.75 $7.31 | ▲ +8.30% | ▲ +9.82% | $7.14 (+5.78%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $5.96 $8.18 | ▲ +37.25% | ▲ +37.73% | $7.14 (+19.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access